Related Experiment Video

Updated: Sep 26, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

[Use of beta-blockers in heart failure]

Moriaki Inoko1, Ryuji Nohara

  • 1Kitano Hospital, Tazuke Kofukai Medical Research Institute.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 21, 2003
PubMed

Insights

Beta-blockers significantly reduce illness and death in heart failure patients. Despite potential side effects, these medications are crucial for managing heart failure and should be actively used.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Clinical trials demonstrate beta-blockers reduce morbidity and mortality in heart failure.
  • Potential mechanisms include protection from catecholamine toxicity, altered beta-adrenergic signaling, reduced apoptosis, decreased myocardial oxygen demand, and antiarrhythmic effects.

Purpose of the Study:

  • To review the benefits and mechanisms of beta-blockers in heart failure treatment.
  • To highlight specific beta-blockers with proven efficacy.

Main Methods:

  • Review of large-scale clinical trials and scientific literature.
  • Analysis of established and proposed mechanisms of action for beta-blockers in heart failure.

Main Results:

  • Metoprolol, bisoprolol, and carvedilol show substantial benefits in heart failure.
  • Gradual initiation and titration are necessary, monitoring for heart failure deterioration.
  • Contraindications include severe bradycardia, high-degree heart block, and decompensated heart failure.

Conclusions:

  • Beta-blockers are essential in heart failure management.
  • Active adoption of beta-blockers is recommended despite potential adverse effects.
  • Careful patient selection and administration are key to maximizing benefits.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...